newsfilter
← Earnings
Earnings Releases·

Rhythm Pharmaceuticals — Third Quarter 2026 Earnings Summary

Rhythm Pharmaceuticals reported third-quarter 2026 net product revenue of $92.1 million from global IMCIVREE sales, representing a 29% sequential increase driven by strong U.S. launch momentum for acquired hypothalamic obesity. The company initiated commercial launches in Japan and secured Health Canada approval for weight management, while advancing its next-generation drug bivamelagon into pivotal Phase 3 trials for Prader-Willi syndrome and acquired HO. Financially, the company recorded a net loss of $42.4 million for the quarter and announced a five-year term loan facility providing access to up to $750 million in capital.

Company
RHYTHM PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology